Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Create alerts with multiple filters including highs/low, comparative values, and turning points. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,062,347
  • Shares Outstanding, K 700,766
  • Annual Sales, $ 55,290 K
  • Annual Income, $ -845,260 K
  • 60-Month Beta 1.33
  • Price/Sales 56.53
  • Price/Cash Flow N/A
  • Price/Book 1.52
Trade ROIV with:

Options Overview Details

View History
  • Implied Volatility 125.80% ( -10.46%)
  • Historical Volatility 61.29%
  • IV Percentile 54%
  • IV Rank 16.53%
  • IV High 448.80% on 01/11/22
  • IV Low 61.84% on 02/25/22
  • Put/Call Vol Ratio 0.45
  • Today's Volume 432
  • Volume Avg (30-Day) 75
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 6,370
  • Open Int (30-Day) 6,230

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.30
  • Number of Estimates 4
  • High Estimate -0.28
  • Low Estimate -0.34
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +18.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.61 +21.22%
on 08/01/22
4.61 -5.10%
on 07/13/22
-0.12 (-2.67%)
since 07/12/22
3-Month
2.88 +51.74%
on 05/13/22
4.89 -10.63%
on 06/29/22
+1.56 (+55.52%)
since 05/12/22

Most Recent Stories

More News
Trade, Manufacturing Data Due Next Week

Monday U.S. Economic Lookahead NAHB home builders' index (Aug.) Featured Earnings Tencent ...

TME : 4.41 (+0.23%)
FN : 100.66 (+2.72%)
ROIV : 4.37 (-2.02%)
WMT : 132.22 (+1.85%)
HD : 314.89 (+1.35%)
SE : 88.71 (+0.15%)
CSCO : 46.61 (+1.55%)
LOW : 206.47 (+2.12%)
ADI : 179.26 (+2.70%)
EL : 275.38 (+1.86%)
AMAT : 110.38 (+4.60%)
DE : 368.16 (+1.72%)
Venus Concept (VERO) Reports Q2 Loss, Misses Revenue Estimates

Venus Concept (VERO) delivered earnings and revenue surprises of -100% and 9.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VERO : 0.5058 (-12.03%)
ROIV : 4.37 (-2.02%)
Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SYBX : 1.1300 (+3.67%)
ROIV : 4.37 (-2.02%)
Exelixis (EXEL) Beats Q2 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 10% and 7.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EXEL : 19.48 (+1.30%)
ROIV : 4.37 (-2.02%)
Strength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength?

Global Blood (GBT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

GBT : 66.75 (+0.27%)
ROIV : 4.37 (-2.02%)
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 50.30 (+1.68%)
ROIV : 4.37 (-2.02%)
Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

Investor call and webcast scheduled for Monday, August 15 at 8:00 a.m. EDTRoivant will host an investor day on Wednesday, September 28 at 11:00 a.m. EDT ...

ROIVW : 0.5722 (-1.33%)
ROIV : 4.37 (-2.02%)
Pfizer (PFE) Discloses Autoimmune Drug Deal With Priovant

Pfizer (PFE) announces the name of the new company that it formed with its partner, Roivant Sciences (ROIV), to develop and market its dual TYK2/JAK1 inhibitor.

PFE : 50.11 (+3.77%)
ABEO : 4.43 (-4.94%)
SESN : 0.7001 (-0.55%)
ROIV : 4.37 (-2.02%)
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical...

ROIVW : 0.5722 (-1.33%)
ROIV : 4.37 (-2.02%)
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral...

ROIVW : 0.5722 (-1.33%)
ROIV : 4.37 (-2.02%)
PFE : 50.11 (+3.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 4.75
2nd Resistance Point 4.65
1st Resistance Point 4.51
Last Price 4.37
1st Support Level 4.27
2nd Support Level 4.17
3rd Support Level 4.03

See More

52-Week High 16.76
Fibonacci 61.8% 11.32
Fibonacci 50% 9.64
Fibonacci 38.2% 7.96
Last Price 4.37
52-Week Low 2.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar